Drugs

MPress Records Releases So Sure's Debut EP Caffeine Drip

Friday, July 10, 2020 - 9:05pm

NEW YORK, July 10, 2020 /PRNewswire-PRWeb/ -- MPress Records recording artists So Sure have released their debut EP Caffeine Drip, with 100% of the proceeds being donated to the ACLU to aid in their advocacy efforts to demand an end to racial injustice and police brutality.

Key Points: 
  • NEW YORK, July 10, 2020 /PRNewswire-PRWeb/ -- MPress Records recording artists So Sure have released their debut EP Caffeine Drip, with 100% of the proceeds being donated to the ACLU to aid in their advocacy efforts to demand an end to racial injustice and police brutality.
  • The full EP, available on all digital platforms and premiered by The Big Takeover , is the first offering from So Sure, which was officially formed during the Covid-19 pandemic.
  • The EP features songs that are all-too-timely and reflect the international frustration and anxiety due to the virus and recent protests sparked by the tragedy in Minneapolis.
  • So Sure's self-produced "Caffeine Drip" was recorded remotely between Savannah, GA, Montgomery, NY and Charleston, SC.

Novanta Inc. Schedules Earnings Release and Conference Call for Thursday, August 6, 2020

Friday, July 10, 2020 - 9:35pm

Novanta Inc. (Nasdaq: NOVT) (the Company), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2020 results on Thursday, August 6, 2020.

Key Points: 
  • Novanta Inc. (Nasdaq: NOVT) (the Company), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2020 results on Thursday, August 6, 2020.
  • The Company will host a conference call on Thursday, August 6, 2020 at 10:00 a.m.
  • To access the call, please dial (888) 346-3959 prior to the scheduled conference call time.
  • This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications.

LSPediA Shapes the Future of Pharmaceutical Serialization with OneScan 4.0 Release

Friday, July 10, 2020 - 6:08pm

WEST BLOOMFIELD, Mich., July 10, 2020 /PRNewswire/ --LSPediA today announced the release of OneScan 4.0, LSPediA's comprehensive DSCSA solution .

Key Points: 
  • WEST BLOOMFIELD, Mich., July 10, 2020 /PRNewswire/ --LSPediA today announced the release of OneScan 4.0, LSPediA's comprehensive DSCSA solution .
  • "What we've accomplished with OneScan 4.0 reflects LSPediA's relentless innovation in the fields of compliance, performance, integration, and automation.
  • OneScan is transformational in the core of system architecture, mobility, and networkability, pushing forward a new and secure supply chain model driven by serialization," said Riya Cao, CEO of LSPediA.
  • With 251 pharmaceutical customers and growing, OneScan interacts with 375 vendors and traces the movement of over 270,000 prescription drug products.

LSPediA Shapes the Future of Pharmaceutical Serialization with OneScan 4.0 Release

Friday, July 10, 2020 - 1:35pm

WEST BLOOMFIELD, Mich., July 10, 2020 /PRNewswire/ --LSPediA today announced the release of OneScan 4.0, LSPediA's comprehensive DSCSA solution.

Key Points: 
  • WEST BLOOMFIELD, Mich., July 10, 2020 /PRNewswire/ --LSPediA today announced the release of OneScan 4.0, LSPediA's comprehensive DSCSA solution.
  • "What we've accomplished with OneScan 4.0 reflects LSPediA's relentless innovation in the fields of compliance, performance, integration, and automation.
  • OneScan is transformational in the core of system architecture, mobility, and networkability, pushing forward a new and secure supply chain model driven by serialization," said Riya Cao, CEO of LSPediA.
  • With 251 pharmaceutical customers and growing, OneScan interacts with 375 vendors and traces the movement of over 270,000 prescription drug products.

Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia

Friday, July 10, 2020 - 12:00pm

TNX-102 SL is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia.

Key Points: 
  • TNX-102 SL is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia.
  • The RELIEF study is a double-blind, randomized, placebo-controlled adaptive design trial designed to evaluate the efficacy and safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg in fibromyalgia.
  • The trial targeted enrollment of approximately 470 participants across approximately 40 U.S. sites.
  • Tonixs lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia.

All-New Version of Popular Digital Multimeter LCR-Reader-MPA Debuts at Nepcon 2019 to Encouraging Results

Friday, July 10, 2020 - 11:00am

WATERLOO, Canada, July 10, 2020 /PRNewswire-PRWeb/ -- Canadian company Siborg Systems Inc. recently showed their newest device, the LCR-Reader-MPA All-in-One Digital Multimeter at Electronic Manufacturing (Nepcon) Korea in May.

Key Points: 
  • WATERLOO, Canada, July 10, 2020 /PRNewswire-PRWeb/ -- Canadian company Siborg Systems Inc. recently showed their newest device, the LCR-Reader-MPA All-in-One Digital Multimeter at Electronic Manufacturing (Nepcon) Korea in May.
  • EMK Nepcon has been proven to be a great place for us to debut devices in the past and this year was no different.
  • Electronic Manufacturing Korea (EMK) has become a globally renowned exhibition for domestic and foeign buyers and is Korea's largest electronics manufacturing exhibition.
  • MPA features gold-plated tweezers integrated with a lightweight multimeter that can automatically determine the test mode and best parameters to use for the component.

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity

Thursday, July 9, 2020 - 11:32pm

BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy.

Key Points: 
  • BOTOX was first approved in June 2019 for the treatment of pediatric patients with upper limb spasticity and in October 2019 for the treatment of pediatric patients with lower limb spasticity, excluding spasticity caused by cerebral palsy.
  • The safety and efficacy of BOTOX as treatment for lower limb spasticity for pediatric patients is supported by a Phase 3 study with more than 300 patients two to 17 years of age with lower limb spasticity because of cerebral palsy.
  • Allergan is committed to providing resources and services, such as the BOTOX Savings Program , to help ensure BOTOX is accessible and affordable to patients.
  • In pediatric patients treated with BOTOX for lower limb spasticity, upper respiratory tract infections were not reported more frequently than placebo.

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

Thursday, July 9, 2020 - 10:24pm

Under the terms of the Research Collaboration and License Agreement (the Agreement), Chiesi Group will pay Bioasis an upfront payment of US$3 million.

Key Points: 
  • Under the terms of the Research Collaboration and License Agreement (the Agreement), Chiesi Group will pay Bioasis an upfront payment of US$3 million.
  • Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.
  • A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group, established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.

CBD Infused Products Popularity Rising Fast in Over-the-counter Retail Stores

Thursday, July 9, 2020 - 2:23pm

Cannabis and, in particular, cannabidiol (CBD), is poised to become one of the most popular and financially successful sectors of consumer processed goods.

Key Points: 
  • Cannabis and, in particular, cannabidiol (CBD), is poised to become one of the most popular and financially successful sectors of consumer processed goods.
  • The article stated that: "As CBD continues to rise in popularity, more over-the-counter (OTC) retailersare getting on board and shifting their strategies to accommodate this new market.
  • As CBD becomes more widely available at over-the-counter retailers and legalization becomes more likely, consumers are considering cannabis as an alternative treatment for health issues, including chronic pain.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Flor Americas Opens Seed Funding Round for Expansion in Global Cannabinoid Export Market

Thursday, July 9, 2020 - 2:02pm

Flor Americas, a vertically integrated manufacturer of pharmaceutical-grade cannabinoids for global markets, today announced the opening of its seed funding round to expand company infrastructure and operations.

Key Points: 
  • Flor Americas, a vertically integrated manufacturer of pharmaceutical-grade cannabinoids for global markets, today announced the opening of its seed funding round to expand company infrastructure and operations.
  • With our company headquarters and manufacturing facility located within Uruguays free-trade zone, Flor Americas is building its network as a leading South American export partner, said Roy McFarland, CEO.
  • Coupled with its wholly owned subsidiary cultivation operation on 1,500 hectares (5.8 square miles), Flor Americas is well-positioned to scale its production to meet global market demand, which grew 91% last year outside the U.S. and Canada.
  • Flor Americas brings together sustainable cultivation methodologies and science-based manufacturing to advance the global cannabis supply chain.